Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Infectious diseases

Fighting the Flu

The antiviral drugs used to treat influenza can lose their effectiveness over time, as the RNA virus spontaneously mutates to evade their mechanisms of action. As a stark example, amantadine, an M2 ion channel inhibitor, is not currently recommended for use in the USA by the Centers of Disease Control and Prevention because of widespread resistance in circulating influenza A viruses.

Now, researchers in Seoul and Daejeon, South Korea, believe they have found a promising new antiviral agent after screening a chemical library of over 2000 synthetic compounds (1). Salinomycin demonstrated potent inhibitory potential against both influenza A and B by seemingly blocking the uptake of viral nuclear protein (NP) into the host cell nucleus and thus restricting the viruses’ ability to replicate effectively. Salinomycin also appeared to block the activity of M2 – but through a different mechanism of action to amantadine.

"Spanish Flu" - The Influenza pandemic lasted for two years from 1918, and effected five-hundred million people worldwide; killing up to one-hundred million of them. It remains the deadliest flu outbreak in recorded history.

The drug produced similar antiviral effects in influenza A virus-infected mouse models. And when used in combination with oseltamivir phosphate (OSV-P) – a neuradamidase inhibitor – its efficacy was further improved. When it comes to translation into the clinic, the researchers are “confident” that a chemical derivative of salinomycin could be developed as an “adjuvant antiviral therapy to treat influenza infections resistant or less sensitive to existing drugs.”

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Y Jang et al. “Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function,” J Virol, 92; 24 p1441-18. (2018) PMID: 30282713
About the Author
Jonathan James

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts